Literature DB >> 32383991

Using 4-vinylcyclohexene diepoxide as a model of menopause for cardiovascular disease.

John P Konhilas1,2, Jessica N Sanchez1,2, Jessica A Regan1,2, Eleni Constantopoulos1,2, Marissa Lopez-Pier3, Danielle K Cannon1, Rinku Skaria1, Laurel A McKee1,2, Hao Chen1,2, Yulia Lipovka1,2, Dennis Pollow1, Heddwen L Brooks1.   

Abstract

There is a sharp rise in cardiovascular disease (CVD) risk and progression with the onset of menopause. The 4-vinylcyclohexene diepoxide (VCD) model of menopause recapitulates the natural, physiological transition through perimenopause to menopause. We hypothesized that menopausal female mice were more susceptible to CVD than pre- or perimenopausal females. Female mice were treated with VCD or vehicle for 20 consecutive days. Premenopausal, perimenopausal, and menopausal mice were administered angiotensin II (ANG II) or subjected to ischemia-reperfusion (I/R). Menopausal females were more susceptible to pathological ANG II-induced cardiac remodeling and cardiac injury from a myocardial infarction (MI), while perimenopausal, like premenopausal, females remained protected. Specifically, ANG II significantly elevated diastolic (130.9 ± 6.0 vs. 114.7 ± 6.2 mmHg) and systolic (156.9 ± 4.8 vs. 141.7 ± 5.0 mmHg) blood pressure and normalized cardiac mass (15.9 ± 1.0 vs. 7.7 ± 1.5%) to a greater extent in menopausal females compared with controls, whereas perimenopausal females demonstrated a similar elevation of diastolic (93.7 ± 2.9 vs. 100.5 ± 4.1 mmHg) and systolic (155.9 ± 7.3 vs. 152.3 ± 6.5 mmHg) blood pressure and normalized cardiac mass (8.3 ± 2.1 vs. 7.5 ± 1.4%) compared with controls. Similarly, menopausal females demonstrated a threefold increase in fibrosis measured by Picrosirus red staining. Finally, hearts of menopausal females (41 ± 5%) showed larger infarct sizes following I/R injury than perimenopausal (18.0 ± 5.6%) and premenopausal (16.2 ± 3.3, 20.1 ± 4.8%) groups. Using the VCD model of menopause, we provide evidence that menopausal females were more susceptible to pathological cardiac remodeling. We suggest that the VCD model of menopause may be critical to better elucidate cellular and molecular mechanisms underlying the transition to CVD susceptibility in menopausal women.NEW & NOTEWORTHY Before menopause, women are protected against cardiovascular disease (CVD) compared with age-matched men; this protection is gradually lost after menopause. We present the first evidence that demonstrates menopausal females are more susceptible to pathological cardiac remodeling while perimenopausal and cycling females are not. The VCD model permits appropriate examination of how increased susceptibility to the pathological process of cardiac remodeling accelerates from pre- to perimenopause to menopause.

Entities:  

Keywords:  4-vinylcyclohexene diepoxide; angiotensin II; cardiac injury; hypertension; menopause

Mesh:

Substances:

Year:  2020        PMID: 32383991      PMCID: PMC7311698          DOI: 10.1152/ajpheart.00555.2019

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  81 in total

1.  miR-29b as a therapeutic agent for angiotensin II-induced cardiac fibrosis by targeting TGF-β/Smad3 signaling.

Authors:  Yang Zhang; Xiao-Ru Huang; Li-Hua Wei; Arthur Ck Chung; Cheuk-Man Yu; Hui-Yao Lan
Journal:  Mol Ther       Date:  2014-02-26       Impact factor: 11.454

Review 2.  Macrophages in cardiac homeostasis, injury responses and progenitor cell mobilisation.

Authors:  Alexander R Pinto; James W Godwin; Nadia A Rosenthal
Journal:  Stem Cell Res       Date:  2014-07-09       Impact factor: 2.020

3.  Effect of ovariectomy and estrogen replacement on cardiovascular disease in heart failure-prone SHHF/Mcc- fa cp rats.

Authors:  L C Sharkey; B J Holycross; S Park; L J Shiry; T M Hoepf; S A McCune; M J Radin
Journal:  J Mol Cell Cardiol       Date:  1999-08       Impact factor: 5.000

Review 4.  Estrogen, natriuretic peptides and the renin-angiotensin system.

Authors:  M L Kuroski de Bold
Journal:  Cardiovasc Res       Date:  1999-03       Impact factor: 10.787

Review 5.  Risk Factors for Myocardial Infarction in Women and Men: A Review of the Current Literature.

Authors:  Lene Rørholm Pedersen; Daria Frestad; Marie Mide Michelsen; Naja Dam Mygind; Hanne Rasmusen; Hannah Elena Suhrs; Eva Prescott
Journal:  Curr Pharm Des       Date:  2016       Impact factor: 3.116

6.  Heart and Estrogen/progestin Replacement Study (HERS): design, methods, and baseline characteristics.

Authors:  D Grady; W Applegate; T Bush; C Furberg; B Riggs; S B Hulley
Journal:  Control Clin Trials       Date:  1998-08

Review 7.  Estrogens and atherosclerosis.

Authors:  J-F Arnal; P Gourdy; R Elhage; B Garmy-Susini; E Delmas; L Brouchet; C Castano; Y Barreira; J C Couloumiers; H Prats; A-C Prats; F Bayard
Journal:  Eur J Endocrinol       Date:  2004-02       Impact factor: 6.664

Review 8.  The VCD Mouse Model of Menopause and Perimenopause for the Study of Sex Differences in Cardiovascular Disease and the Metabolic Syndrome.

Authors:  H L Brooks; D P Pollow; P B Hoyer
Journal:  Physiology (Bethesda)       Date:  2016-07

9.  Soy diet worsens heart disease in mice.

Authors:  Brian L Stauffer; John P Konhilas; Elizabeth D Luczak; Leslie A Leinwand
Journal:  J Clin Invest       Date:  2006-01       Impact factor: 14.808

10.  The role of mouse strain differences in the susceptibility to fibrosis: a systematic review.

Authors:  Louise Walkin; Sarah E Herrick; Angela Summers; Paul E Brenchley; Catherine M Hoff; Ron Korstanje; Peter J Margetts
Journal:  Fibrogenesis Tissue Repair       Date:  2013-09-25
View more
  1 in total

Review 1.  Guidelines for in vivo mouse models of myocardial infarction.

Authors:  Merry L Lindsey; Keith R Brunt; Jonathan A Kirk; Petra Kleinbongard; John W Calvert; Lisandra E de Castro Brás; Kristine Y DeLeon-Pennell; Dominic P Del Re; Nikolaos G Frangogiannis; Stefan Frantz; Richard J Gumina; Ganesh V Halade; Steven P Jones; Rebecca H Ritchie; Francis G Spinale; Edward B Thorp; Crystal M Ripplinger; Zamaneh Kassiri
Journal:  Am J Physiol Heart Circ Physiol       Date:  2021-10-08       Impact factor: 5.125

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.